American physicians choose surgical interventions for patients with cardiovascular conditions more aggressively than do their European counterparts, who tend to try medical interventions for longer. Cor Therapeutics Inc., whose partner Schering-Plough Corp. last week received pan-European approval for Integrilin eptifibatide in acute coronary syndromes (ACS), hopes that the difference will translate into increased European sales.

Integrilin is a GPIIb/IIIa inhibitor approved to prevent early myocardial infarction in patients with ACS.